CENTRAL TRUST Co lowered its stake in Bristol-Myers Squibb Co (NYSE:BMY) by 1.0% during the 4th quarter, HoldingsChannel reports. The firm owned 182,375 shares of the biopharmaceutical company’s stock after selling 1,812 shares during the quarter. CENTRAL TRUST Co’s holdings in Bristol-Myers Squibb were worth $11,176,000 at the end of the most recent reporting period.
A number of other hedge funds also recently made changes to their positions in BMY. Advisor Partners LLC raised its position in shares of Bristol-Myers Squibb by 6.9% during the 3rd quarter. Advisor Partners LLC now owns 36,961 shares of the biopharmaceutical company’s stock valued at $2,356,000 after buying an additional 2,382 shares in the last quarter. Oppenheimer & Co. Inc. raised its position in shares of Bristol-Myers Squibb by 2.5% during the 2nd quarter. Oppenheimer & Co. Inc. now owns 358,509 shares of the biopharmaceutical company’s stock valued at $19,976,000 after buying an additional 8,813 shares in the last quarter. Israel Discount Bank of New York raised its position in shares of Bristol-Myers Squibb by 31.8% during the 2nd quarter. Israel Discount Bank of New York now owns 10,515 shares of the biopharmaceutical company’s stock valued at $586,000 after buying an additional 2,540 shares in the last quarter. Dividend Assets Capital LLC purchased a new stake in shares of Bristol-Myers Squibb during the 2nd quarter valued at about $737,000. Finally, Van ECK Associates Corp raised its position in shares of Bristol-Myers Squibb by 0.7% during the 3rd quarter. Van ECK Associates Corp now owns 791,275 shares of the biopharmaceutical company’s stock valued at $50,436,000 after buying an additional 5,451 shares in the last quarter. Institutional investors and hedge funds own 69.82% of the company’s stock.
Shares of Bristol-Myers Squibb Co (NYSE:BMY) opened at $67.35 on Wednesday. The company has a debt-to-equity ratio of 0.59, a current ratio of 1.55 and a quick ratio of 1.43. Bristol-Myers Squibb Co has a 1 year low of $51.56 and a 1 year high of $70.05. The firm has a market cap of $112,582.92, a PE ratio of 22.91, a P/E/G ratio of 2.14 and a beta of 1.09.
Bristol-Myers Squibb (NYSE:BMY) last posted its quarterly earnings data on Monday, February 5th. The biopharmaceutical company reported $0.68 earnings per share for the quarter, topping the Zacks’ consensus estimate of $0.67 by $0.01. Bristol-Myers Squibb had a net margin of 4.85% and a return on equity of 35.43%. The company had revenue of $5.45 billion for the quarter, compared to analyst estimates of $5.35 billion. During the same period in the prior year, the company posted $0.63 EPS. The firm’s revenue for the quarter was up 3.9% on a year-over-year basis. equities research analysts predict that Bristol-Myers Squibb Co will post 3.21 earnings per share for the current fiscal year.
The company also recently disclosed a quarterly dividend, which was paid on Thursday, February 1st. Investors of record on Friday, January 5th were given a $0.40 dividend. This is a positive change from Bristol-Myers Squibb’s previous quarterly dividend of $0.39. This represents a $1.60 dividend on an annualized basis and a yield of 2.38%. The ex-dividend date of this dividend was Thursday, January 4th. Bristol-Myers Squibb’s dividend payout ratio is 271.19%.
Several analysts have recently issued reports on the stock. Citigroup set a $78.00 target price on shares of Bristol-Myers Squibb and gave the company a “buy” rating in a research report on Friday, February 16th. BMO Capital Markets set a $51.00 target price on shares of Bristol-Myers Squibb and gave the company a “sell” rating in a research report on Wednesday, February 14th. Vetr upgraded shares of Bristol-Myers Squibb from a “sell” rating to a “hold” rating and set a $60.72 target price on the stock in a research report on Thursday, February 1st. Piper Jaffray Companies restated a “hold” rating and set a $60.00 target price on shares of Bristol-Myers Squibb in a research report on Friday, October 27th. Finally, Leerink Swann upped their target price on shares of Bristol-Myers Squibb from $71.00 to $76.00 and gave the company a “positive” rating in a research report on Tuesday, February 6th. Three investment analysts have rated the stock with a sell rating, eight have issued a hold rating and nine have assigned a buy rating to the company’s stock. Bristol-Myers Squibb currently has an average rating of “Hold” and an average target price of $66.73.
In other Bristol-Myers Squibb news, EVP Sandra Leung sold 156,582 shares of the company’s stock in a transaction dated Monday, December 4th. The shares were sold at an average price of $63.37, for a total value of $9,922,601.34. Following the transaction, the executive vice president now directly owns 584,373 shares in the company, valued at approximately $37,031,717.01. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, EVP Thomas J. Jr. Lynch sold 5,300 shares of the company’s stock in a transaction dated Tuesday, December 12th. The stock was sold at an average price of $63.24, for a total transaction of $335,172.00. Following the completion of the transaction, the executive vice president now owns 9,251 shares in the company, valued at $585,033.24. The disclosure for this sale can be found here. Corporate insiders own 0.23% of the company’s stock.
ILLEGAL ACTIVITY NOTICE: “Bristol-Myers Squibb Co (BMY) Shares Sold by CENTRAL TRUST Co” was published by Stock Observer and is owned by of Stock Observer. If you are reading this news story on another domain, it was copied illegally and republished in violation of US & international copyright and trademark law. The correct version of this news story can be viewed at https://www.thestockobserver.com/2018/02/21/bristol-myers-squibb-co-bmy-shares-sold-by-central-trust-co.html.
About Bristol-Myers Squibb
Bristol-Myers Squibb Company is engaged in the discovery, development, licensing, manufacturing, marketing, distribution and sale of biopharmaceutical products. The Company’s pharmaceutical products include chemically synthesized drugs, or small molecules, and products produced from biological processes called biologics.
Want to see what other hedge funds are holding BMY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Bristol-Myers Squibb Co (NYSE:BMY).
Receive News & Ratings for Bristol-Myers Squibb Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bristol-Myers Squibb and related companies with MarketBeat.com's FREE daily email newsletter.